大黄利胆片对非酒精性脂肪性肝病湿热蕴结证患者血清IL-1RA、IL-1β<\i>、IL-18水平和肠道菌群的影响

Effect of Dahuang Lidan Tablets on Serum IL-1RA, IL-1β<\i>, IL-18 Levels and Intestinal Flora in Patients with Non-alcoholic Fatty Liver Disease in Damp-heat Accumulation Pattern

  • 摘要: 目的 观察大黄利胆片对非酒精性脂肪性肝病湿热蕴结证患者的疗效,并探讨其对血清白细胞介素-1受体拮抗剂(IL-1RA)、IL-1β、IL-18水平以及肠道菌群的影响。方法 选取2017年6月至2019年4月甘肃省中医院收治非酒精性脂肪性肝病患者86例,按随机数字表法分为对照组和观察组,各43例。2组按指南给予常规治疗措施;对照组给予水飞蓟宾胶囊口服,每日3次,每次4粒;观察组在对照组治疗基础上给予大黄利胆片口服,每次2片,每日3次。2组连续治疗12周。比较2组肝功能和血脂水平、湿热蕴结证证候评分、临床疗效、血清IL-1RA、IL-1β、IL-18水平及肠道菌群的变化。结果 治疗后观察组谷草转氨酶(AST)、谷丙转氨酶(ALT)和低密度脂蛋白(LDL-C)、总胆固醇(TC)、甘油三酯(TG)以及湿热蕴结证证候评分显著低于对照组,高密度脂蛋白(HDL-C)明显高于对照组(P<0.01);观察组总有效率显著高于对照组(P<0.01);观察组血清IL-1RA水平显著高于对照组(P<0.05),IL-1β、IL-18水平明显低于对照组(P<0.05);观察组双歧杆菌、乳酸杆菌显著高于对照组(P<0.05),大肠杆菌明显低于对照组(P<0.05)。结论 大黄利胆片治疗非酒精性脂肪性肝病湿热蕴结证疗效确切,其作用机制可能与调节血清IL-1RA、IL-1β、IL-18水平以及肠道菌群有关。

     

    Abstract: OBJECTIVE To observe the curative effect of Dahuang Lidan tablets on patients with non-alcoholic fatty liver disease in damp-heat accumulation pattern, and to explore its effects on serum interleukin-1 receptor antagonist (IL-1RA), interleukin (IL)-1β, IL-18 levels and intestinal flora. METHODS The enrolled cases were 86 patients with non-alcoholic fatty liver disease, admitted to Gansu Provincial Hospital of TCM from June 2017 to April 2019. They were divided into the control group and the observation group according to the random number table, with 43 cases in each group. The two groups were given conventional treatment measures according to the guidelines. The control group was given Silybin capsules, 3 times a day, 4 tablets each time. The observation group was treated orally with Dahuang Lidan tablets, 2 tablets each time, 3 times a day, based on the treatment of the control group. Both groups were treated continuously for 12 weeks. The liver function, blood lipid levels, damp-heat accumulation syndrome score, clinical efficacy, serum IL-1RA, IL-1β, IL-18 levels, and changes of intestinal flora were compared between the two groups. RESULTS After treatment, the aspartate aminotransferase (AST), alanine aminotransferase (ALT), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), and damp-heat accumulation syndrome score in the observation group were significantly lower than those in the control group, while its high-density lipoprotein cholesterol (HDL-C) was notably higher than that of the control group (P<0.01). The total effective rate of the observation group was 93.02%, and the control group was 74.42%. As for the total effective rate, the observation group was conspicuously higher than that of the control group (P<0.01). After treatment, the serum IL-1RA level of the observation group was significantly higher than that of the control group. The levels of IL-18, IL-1β were remarkably lower than those of the control group (P<0.05). The numbers of Bifidobacterium and Lactobacillus in the observation group were strikingly higher than those in the control group after treatment, and the number of Escherichia coli was prominently lower than that of the control group (P<0.05). There was no conspicuous difference in the changes of Bifidobacterium, Lactobacillus and Escherichia coli before and after treatment in the control group (P>0.05). There was no significant difference in the changes of Enterococcus between the two groups before and after treatment (P>0.05). CONCLUSION Dahuang Lidan tablets have a definite effect in treating non-alcoholic fatty liver disease with accumulation of damp-heat syndrome. Its mechanism may be related to the regulation of serum IL-1RA, IL-1β, IL-18 levels, and intestinal flora.